Biotechnology company with laboratories at Oxford in England and an American office, founded in 2018 to work on small molecules that induce autophagy, the cell's process for clearing damaged material. Screens for and develops compounds intended to treat neurodegenerative and other age related diseases, works with academic founders in the autophagy field, and has raised venture funding to take programmes into preclinical development.
No hay comentarios disponibles.
Deja tu valoración & comentario